重要新闻 1. 国务院：政府部门应当科学合理确定政务数据共享属性，不得通过擅自增设条件等方式阻碍、影响政 务数据共享 李强签署国务院令，公布《政务数据共享条例》。条例提到，政府部门应当科学合理确定政务数据共享 属性，不得通过擅自增设条件等方式阻碍、影响政务数据共享。对属于有条件共享类的政务数据，政府 部门应当在政务数据目录中列明共享范围、使用用途等共享使用条件。对属于不予共享类的政务数据， 政府部门应当在政务数据目录中列明理由，并明确相应的法律、行政法规以及国务院决定依据。（新华 社） 2. 商务部等五部门组织开展2025年新能源汽车下乡活动，特斯拉Model 3、Model Y车型在列 工业和信息化部、国家发展改革委、农业农村部、商务部、国家能源局组织开展2025年新能源汽车下乡 活动。选取一批新能源汽车推广比例不高、市场潜力较大的典型县域城市，举行若干场专场活动；以此 为中心辐射周边乡镇，结合地区特点开展若干场特色活动。与县域充换电设施补短板试点、智能网联汽 车"车路云一体化"试点等工作形成协同效应，推动优质资源向乡村地区倾斜。其中，特斯拉Model 3、 Model Y车型在列。 3. 商务部：希望欧方 ...

化学制药板块短线走低，华纳药厂跌超9%，天宇股份（300702）、舒泰神（300204）、多瑞医药 （301075）、海创药业等跟跌。 ...

Policy Developments - The State Administration for Market Regulation announced ten typical cases of illegal advertising, with multiple cases involving the medical field, including one case related to medical device advertising and two cases concerning illegal drug advertising [2] - As of the end of April, a total of 11,459 illegal advertising cases were investigated, resulting in fines totaling 88.309 million yuan [2] Drug and Device Approvals - Shuyou Shen announced that its subsidiary received a notice from the National Medical Products Administration regarding the conditional listing application for "STSP-0601," a drug aimed at promoting rapid hemostasis for adult patients with hemophilia A or B [4] - Lepu Medical received registration approval from the NMPA for its self-developed polylactic acid facial filler, known as "童颜针," marking a significant milestone in the dermatology field [5] Capital Market Activities - Baiyang Pharmaceutical announced the release of 5.3 million shares from pledge by its controlling shareholder, representing 1.44% of the shares held by the shareholder and 1.01% of the company's total share capital [7] - Jincheng Pharmaceutical provided a guarantee of 5 million yuan for its wholly-owned subsidiary, Shandong Jincheng Biological Pharmaceutical Co., Ltd. [8] Industry Developments - AstraZeneca announced significant progress in the treatment of EGFR mutation-positive non-small cell lung cancer with MET amplification, with interim results from the SACHI Phase III study to be presented at the ASCO annual meeting [10][11] - Yuheng Pharmaceutical signed a market promotion service agreement with Eisai (China) Pharmaceutical for "Mikobao," which will enhance Yuheng's product pipeline and increase revenue [12] - New Scene Intelligence authorized BeiGene to develop universal cell therapy drugs based on a specific TCR molecule, with potential milestone payments and revenue sharing [13] - Buchang Pharmaceutical withdrew its clinical trial application for a rabies vaccine, indicating the need for further research before resubmission [14] Public Opinion Alerts - Huaxi Biological responded to recent controversies regarding recombinant collagen, emphasizing the importance of product quality over naming conventions [16] - Kangning Jerey announced a share transfer agreement involving 14.6 million shares, amounting to 117 million HKD [17]

各位老铁，这里是帮主郑重的收评时间。今天这市场啊，就像端午节包粽子——外面看着热闹，里头藏着门道。沪指涨了0.43%，深成指和创业板指也跟着 回暖，但仔细看，近3400只个股上涨的背后，资金明显在玩"抓大放小"的游戏。咱们今天就拆解拆解，这反弹里到底藏着啥玄机。 先说指数反弹的"底气"从哪来 今天市场能反弹，跟政策预期升温脱不了干系。最近市场对稳增长政策的期待越来越强，加上外资回流的迹象，让不少观望资金试探性进场。不过成交量只 放量了4个亿，说明大家还是有点犹豫，就像煮粽子时火候不够，米粒还没完全开花。这时候得盯紧北向资金的动向，它们要是持续加仓，反弹才有持续 性。 创新药板块爆发：政策松绑+研发提速的双击 创新药今天集体嗨了，舒泰神、海南海药这些票涨停，可不是偶然。去年开始，创新药审批流程大幅缩短，加上老龄化带来的刚性需求，这个板块就像压紧 的弹簧。我跟药企研发总监聊过，现在一款创新药从立项到上市周期比三年前快了30%，这就好比做菜从慢炖变成高压锅，效率上去了，利润空间自然就打 开了。不过要提醒老铁们，别光看涨停就追高，得看企业真正的研发管线厚度，有些票可能只是蹭概念。 银行股稳如泰山：高股息成避风港 沪农 ...

Core Viewpoint - The article summarizes important announcements from various listed companies in the Shanghai and Shenzhen stock markets, providing insights for investors regarding recent developments and their potential impacts on company performance. Company Announcements - Shuyou Shen's application for conditional listing of STSP-0601 has been accepted by the National Medical Products Administration, aimed at treating bleeding in adult patients with hemophilia A or B, but its impact on current performance is uncertain [3] - Debang Co. has clarified that it has not yet applied autonomous driving logistics vehicles, and this concept will not affect its performance [4] - Hu Xianfu has been elected as the chairman of China Shipbuilding, with a term until the board's term ends [7] - Baili Electric reported that its involvement in controlled nuclear fusion projects has minimal revenue impact, accounting for less than 1% of total revenue in 2024 [8] - Wanrun Co.'s chairman Huang Yiwu has resigned due to work adjustments, and he will not hold any positions in the company post-resignation [9] - Kexing Pharmaceutical announced that its innovative drug projects are still in the preclinical stage, highlighting the high risks and uncertainties involved in drug development [10] Performance Metrics - Sairisi reported that the cumulative sales of the Wanjie M9 reached 50,500 units from January to May, a year-on-year increase of 19.46% [11] - Guangzhou Port expects a 4.3% year-on-year increase in container throughput for May, with a total of 2.309 million TEUs [12] Shareholding Changes - Guokang Biochemical announced that major shareholders plan to reduce their holdings by up to 6% of the company's shares [13] - Far East Co. plans to reduce its holdings by up to 2.30% due to funding needs [14] Share Buybacks - Goodway plans to repurchase shares worth between 100 million and 150 million yuan, with a maximum price of 53 yuan per share [15] - Industrial Fulian has repurchased 7,697,400 shares, using a total of approximately 147 million yuan [16][17] Strategic Partnerships - Siwei Tuxin signed a strategic cooperation framework agreement with Alibaba Cloud to enhance its automotive intelligence strategy over the next five years [18] - Del Co. plans to invest approximately 300 million yuan in new lithium battery pilot and industrialization projects [19]

Core Viewpoint - The stock price of Shutaishen (300204.SZ) has surged over 300% in two months, reaching 31.80 CNY per share, with a market capitalization of 15.2 billion CNY, driven by positive clinical trial results and announcements [1][5]. Group 1: Stock Performance - On June 3, Shutaishen closed at a limit-up price of 31.80 CNY, surpassing the 30 CNY mark, with a total market value of 15.2 billion CNY [1]. - The stock price was approximately 7.5 CNY in early April, indicating a price increase of over 300% in just two months [1]. - The main upward trend began on May 20, with the stock rising from 11 CNY to 31.80 CNY, a cumulative increase of over 188% [1]. Group 2: Clinical Trial Announcements - On May 28, Shutaishen announced preliminary results of the STSA-1002 injection for ARDS, showing good safety and tolerability, which further fueled investor interest [5]. - On June 3, the company announced that the conditional listing application for STSP-0601 was accepted by the National Medical Products Administration, which is intended for rapid hemostasis in hemophilia patients [5]. Group 3: Research Reports and Market Sentiment - Following the stock price surge, Caixin Securities published two research reports on Shutaishen, both maintaining a "buy" rating and projecting revenues of 294 million CNY, 448 million CNY, and 1.096 billion CNY for 2025-2027 [7]. - The last research report prior to this was published in March 2022, indicating a significant gap in coverage [8]. Group 4: Industry Trends - The recent surge in Shutaishen's stock price is attributed to a broader trend in the innovative drug sector, driven by accelerated commercialization of domestic innovative drugs and significant licensing agreements [11]. - The upcoming ASCO annual meeting is expected to showcase over 70 research results from Chinese pharmaceutical companies, highlighting the global presence of domestic innovative drugs [11]. - Analysts believe that the innovative drug sector will continue to be a key investment theme, supported by favorable policies and market conditions [11].

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets have released important announcements, providing insights for investors [1] Company Announcements - Shuyou Shen's subsidiary received acceptance for the conditional listing application of STSP-0601, aimed at treating bleeding in adult patients with hemophilia A or B, but its impact on current performance is not significant [3] - Debang Co. clarified that it has not yet applied unmanned logistics vehicles, and this concept will not affect its performance [4] - Hu Xianfu was elected as the chairman of China Shipbuilding, with a term until the board's expiration [6] - Baili Electric reported that its involvement in controlled nuclear fusion projects has minimal revenue impact, accounting for less than 1% of total revenue in 2024 [7] - Wanrun Co.'s chairman Huang Yiwu resigned due to work adjustments, and he will not hold any position in the company post-resignation [8] Performance Expectations - Guangzhou Port expects a 4.3% year-on-year increase in container throughput for May, with a total of 2.309 million TEUs, while total cargo throughput is projected to decline by 0.3% [10] Shareholding Changes - Far East Co. plans to reduce its shareholding by up to 2.30%, equating to a maximum of 51,045,200 shares, due to funding needs [12] Share Buybacks - Industrial Fulian has repurchased 7,697,400 shares for a total of approximately 147 million yuan, with a maximum repurchase price of 20 yuan per share [14] Strategic Partnerships - Siwei Tuxin signed a strategic cooperation framework agreement with Alibaba Cloud to enhance collaboration in various fields, including intelligent automotive strategies [16] - Del Co. plans to invest approximately 300 million yuan in new lithium battery pilot and industrialization projects, as well as smart motor industrialization projects [17]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Group 1 - The innovative drug concept has been thriving this year, leading to a gradual recovery in the pharmaceutical sector, with the innovative drug sector index rising by 3.38% to 1175.97 points as of June 3, and a quarterly increase of 15.32% and an annual increase of 21.86% [1][4] - Several stocks in the innovative drug sector have reached historical highs, with Shuyou Shen's stock price increasing by over 329% this year, and other companies like Guanhao Biological, Warner Pharmaceuticals, and Kexing Pharmaceuticals also showing significant price increases [1][2] - The pharmaceutical sector has experienced a long adjustment period since 2021, with a maximum cumulative decline of 50.9%, attributed to policy changes and a shift in the industry's growth dynamics [3][5] Group 2 - Shuyou Shen's stock saw a dramatic increase of 169.72% from May 21 to June 3, reaching a historical high of 31.8 yuan per share, driven by breakthroughs in drug development [2][4] - Innovative pharmaceutical companies have been actively engaging in overseas licensing deals, with Heng Rui Pharmaceutical achieving nearly $2 billion in transactions within a short period, indicating a robust market for innovative drug licensing [2][5] - The current environment is favorable for innovative drug investments, with a focus on strong certainty in innovative drug exports and a combination of innovative and generic products, as well as attention to data releases from major conferences [4][5]

人气及连板股分析 连板晋级率回升至35.3%，最高标德邦股份晋级5连板，但受到整个无人车辆概念的退潮拖累，尾盘遭遇巨量炸板分歧。整个高位人气股仍呈现两极分化， 王子新材、京华激光遭遇2连跌停的同时，均瑶健康、合兴股份两只此前断板股双双以"地天板"形式完成反包，因此类似断板反包的N型走势或成为近期一 批新抱团品种的新常态。高位股持续分化的同时，银行、创新药等大市值体量板块的强趋势行情仍不断得以强化。其中将要入选沪深300、上证180等指数的 沪农商行涨停并创出3年多新高，也是银行板块更是时隔2年多后再现涨停个股。在市场短线投机接力方向分歧之际，一些趋势主导的板块仍容易对资金形成 虹吸。 | 连板数 | 晋级率 | | 2025-6-3 | | --- | --- | --- | --- | | 4讲5 | 1/2=50% | 德邦股份(无人物流车) | | | 3 #4 | 2/2=100% | 御银股份 (数字货币) | | | 2讲3 | 3/13=23% | 恒宝股份 (数字货币+机器人) | | | | | 海联金汇(数字货币) | | | | | 哈三联(创新药+医美) | | | | | 万邦德(创 ...